Making endocrine pancreas cells at will is one of the major goals of cellular based therapies for diabetes. The experimentally induced conversion of hepatocytes into pancreatic cells, using a modified version of the transcription factor Pdx-1, may provide an alternative to stem cell approaches.
The promise of tissue replacement therapy -that is, of replacing a body's damaged or diseased cells with healthy or genetically corrected cells-has driven an intensive search for methods to produce the desired cells or tissue types in vitro. For example, the ability to generate insulin-producing pancreatic β β cells in vitro, which could be transplanted into patients, would be invaluable in treating hundreds of millions of diabetics worldwide. Most of the research aimed at producing therapeutically useful cells has focused on the identification, isolation and in vitro differentiation of stem cells.
As reported recently in Current Biology, Horb and co-workers [1] have taken an alternative approach, attempting to exploit the phenomenon of 'transdifferentiation' -the conversion of one differentiated cell type into another. They have been able to induce the conversion of liver cells into both endocrine and exocrine pancreatic cells by expressing in hepatocytes a modified version of the pancreatic homeobox gene Pdx-1. We shall review their results, highlighting the significant advances and commenting on some of the future hurdles that need to be tackled before this type of approach might reach its therapeutic potential.
Transdifferentiation is the term used to describe the process whereby one differentiated cell type transforms into another differentiated cell or tissue [2] . In vivo, this phenomenon is more commonly known as metaplasia and is frequently deemed a premalignant lesion [3, 4] . Transdifferentiation between the liver and pancreas has been observed in human autopsy and biopsy specimens. For example, transformation of many endodermal organs into hepatic tissue has been observed in pathology specimens of digestive tract tumors from adenocarcinoma of the stomach to pancreatic islet cell and ductular tumors [5] . Liver to pancreas transformations have also been observed in liver cirrhosis, where the regenerating liver adopts an acinar histology resembling exocrine pancreatic tissue [6] . Experimental models for transdifferentia -tion between liver and the exocrine pancreas have also been documented. For example, liver can be converted into exocrine pancreas tissue in rats treated with polychlorinated biphenyls [7] or in fish treated with diethylnitrosamine [8] . But in all reported cases of pancreas transdifferentiated from liver, only exocrine tissue and never endocrine pancreas tissue has been observed.
With the aim of converting liver cells into pancreas tissue, including endocrine cells, Horb et al. [1] developed a transgenic strategy using Xenopus and expressed a superactive form of the pancreatic homeobox gene Pdx-1 (also known as Xlhbox8) [9] in the Xenopus embryonic liver [1] . Pdx-1 is a homeobox transcription factor which is thought to be a key determinant of pancreatic development. Targeted deletion of Pdx-1 in mouse results in a failure of the pancreas to form [10, 11] and Pdx-1 mutations in humans have been linked to pancreatic agenesis [12] . These results suggested that Pdx-1 might be a 'master regulatory' gene specifying the pancreatic lineage [13] , though earlier attempts to produce ectopic pancreas tissue by overexpressing Pdx-1 were unsuccessful [14, 15] .
Horb et al. [1] reasoned that the earlier attempts to induce a complete conversion of liver into pancreatic tissue might have failed because Pdx-1 normally needs other pancreas-specific cofactors to transactivate its target genes and hence initiate pancreatic development. They sought to overcome this by fusing the potent VP16 transcriptional activation domain from Herpes simplex virus [16] to Pdx-1, thus making a super-active form of the protein, which they call Xlhbox8-VP16, that might not require cofactors.
Using the liver-specific transthyretin (TTR) promoter, Xlhbox8-VP16 was expressed in the liver buds of transgenic embryos [1] . The transgene construct also included a green fluorescent protein (GFP) reporter under control of the pancreas-specific elastase promoter, which directs expression in both the exocrine and endocrine pancreas. This made it possible for Horb et al. Importantly, Horb et al. [1] found that the Xlhbox8-VP16 transgene was not expressed until a day or so after the liver bud had started expressing hepatic markers. They argue this indicates that they are observing a transdifferentiation event, rather than redirecting the development of some naïve endodermal precursor common to the liver and pancreatic lineage. To further test this, the authors transfected the human hepatoma-derived cell line HepG2, which exhibits a number of characteristics of differentiated hepatocytes, with the TTR-Xlhbox8:VP16 construct [17] . In agreement with their observations on transgenic embryos, they found that Xlhbox8:VP16 induced in the HepG2 cells 'pancreatic' GFP expression from the elastase:GFP reporter, expression of endogenous exocrine and endocrine pancreatic markers, and downregulation of liver gene expression [1] .
The take-home message from these 'proof-ofprinciple' experiments is that it might be possible to convert a patient's own hepatocytes into endocrine pancreatic cells (Figure 1) as a means Is this approach applicable to other cell types? Transdifferentiation phenomena are not limited to endodermal organs and have been observed in both mesodermal and ectodermal tissues [18, 19] . It appears, though, that the closer the embryological relationship between two cell types, the more likely one is to observe a conversion from one to the other [2, 19] . Indeed, the liver and pancreatic lineages arise from a common embryonic endoderm cell population in the anterior foregut. The decision between a hepatic or pancreatic fate is thought to be regulated by only few key developmental steps, such as fibroblast growth factor from the adjacent heart promoting the hepatic over a pancreatic fate [20] , and the subsequent expression of Pdx-1 in the presumptive pancreatic lineage (Figure 1) . The ability ectopically to activate one of the key developmental regulators underpins the success of the experiments reported by Horb et al. [1] . In order for similar approaches to be used with other cell types, a detailed knowledge of their key developmental regulators would be required.
Another important parameter in transdifferentiation is the developmental stage or differentiation state of the cells. It appears that the more immature, fetal or transformed the cell type, the more readily transdifferentiation can occur -as mentioned above, it is often associated with premalignant neoplasias [3] . It could be argued that both the liver bud and the tumorderived HepG2 cells are not true differentiated hepatocytes, but only partially differentiated hepatoblast-type cells which may be more plastic in their ability to transdifferentiate. Thus, to be therapeutically useful it will be important in the future to test if adult hepatocytes can be induced to form functioning pancreatic tissue. A test of this might be to express Pdx1-VP16 in the liver of adult mice with an inducible transgenic strategy and determine if the mature hepatocytes can be converted to pancreas.
Clearly, there are still numerous steps to be rigorously examined before this approach can be considered a viable therapeutic option. However, Horb et al. 
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